bluebird bio, Inc.

bluebirdbio.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 14, 2025. Its latest SEC filing is a 15-12G from Jun 12, 2025.

The sections below describe the company as of the FY2024 annual report.

How Did They Make Money?

revenue

Segment	Share	Revenue
ZYNTEGLO	74%
SKYSONA	12%
LYFGENIA	14%

Did Revenues Turn Into Profits?

No. It lost $240.7M in FY2024.

Operating income, FY2024

−323% of revenue

▲ +11% (Loss) vs FY2023 (−$244.3M, −828%)

Net income, FY2024

−287% of revenue

▲ +14% (Loss) vs FY2023 (−$211.9M, −718%)

Free cash flow, FY2024

−313% of revenue

▲ +10% (Loss) vs FY2023 (−$239.2M, −811%)

How Were They Changing?

Since the FY2024 annual report

Latest quarter: Q1 FY2025, the three months to Mar 31, 2025

Revenue: ▲ +108%; vs $18.6M in Q1 FY2024

ZYNTEGLO share of revenue vs 100.0% in Q1 FY2024

Revenue over time

ZYNTEGLO SKYSONA LYFGENIA

$100M$50M$0

FY2022 FY2023 FY2024

Comments